Skip to Content
Merck
All Photos(1)

Key Documents

567020

Sigma-Aldrich

Simvastatin

≥98% (HPLC), solid, HMG-CoA reductase inhibitor, Calbiochem®

Synonym(s):

Simvastatin, MK-733, L-Type Calcium Channel Blocker VI

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C25H38O5
CAS Number:
Molecular Weight:
418.57
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Simvastatin, A lipophilic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that blocks Ras function through inhibition of farnesylation.

Quality Level

Assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

off-white

cation traces

heavy metals: ≤20 ppm
heavy metals: <20 ppm

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1

InChI key

RYMZZMVNJRMUDD-HGQWONQESA-N

General description

A lipophilic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that blocks Ras function through inhibition of farnesylation. Also inhibits glucose-induced Ca2+ signaling and insulin secretion by blocking L-type Ca2+ channels in rat islet β-cells. Inhibits cell proliferation of human smooth muscle cells. Note: this product is supplied in an inactive form and requires treatment with NaOH in EtOH followed by neutralization to pH 7.2 for activation.
A lipophilic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that blocks Ras function through inhibition of farnesylation. Also inhibits glucose-induced Ca2+-signaling and insulin secretion by blocking L-type Ca2+ channels in rat islet β-cells. Inhibits cell proliferation of human smooth muscle cells. Note: This product is supplied in an inactive form and requires treatment with NaOH in ethanol followed by neutralization to pH 7.2 for activation.

Biochem/physiol Actions

Cell permeable: no
Primary Target
farnesylation
Product does not compete with ATP.
Reversible: no

Warning

Toxicity: Standard Handling (A)

Preparation Note

Dissolve 50 mg in 1 ml in ethanol and add 0.813 ml of 1N NaOH. Adjust the pH to 7.2 by adding small quantities of 1N HCl before use.

Reconstitution

Following reconstitution in ethanol-NaOH, aliquot and freeze (-20°C) Ethanol-NaOH solutions are stable for up to 1 month at -20°C. Neutralized solutions should be used immediately.

Other Notes

Yada, T., et al. 1999. Br. J. Pharmacol. 126, 1205.
Clutterbuck, R.D., et al. 1998. Br. J. Haematol. 102, 522.
Yokoyama, K., et al. 1998. Mol. Biochem. Parasitol. 94, 87.
Negre-Aminou, P., et al. 1997. Biochim. Biophys. Acta 1345, 259.
Vrtovsnik, F., et al. 1997. Kidney Int. 52, 1016.
Keyomarsi, K., et al. 1991. Cancer Res.51, 3602.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lívia Teixeira et al.
Frontiers in immunology, 13, 820131-820131 (2022-03-08)
Coronavirus disease 2019 (COVID-19) is currently a worldwide emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In observational clinical studies, statins have been identified as beneficial to hospitalized patients with COVID-19. However, experimental evidence of underlying statins protection
Bingjiao Zhao et al.
Journal of applied biomaterials & functional materials, 18, 2280800019900094-2280800019900094 (2020-09-16)
Simvastatin (SIM) has been documented to induce the osteogenic differentiation of periodontal ligament stem cells (PDLSCs). To establish an efficient release system for periodontal regeneration, a polycaprolactone (PCL) membrane scaffold containing SIM was electrospun and evaluated. The obtained PCL-SIM membrane
Angela Jeong et al.
ACS chemical biology, 17(10), 2863-2876 (2022-09-16)
Dysregulation of protein prenylation has been implicated in many diseases, including Alzheimer's disease (AD). Prenylomic analysis, the combination of metabolic incorporation of an isoprenoid analogue (C15AlkOPP) into prenylated proteins with a bottom-up proteomic analysis, has allowed the identification of prenylated
Patrícia M R Pereira et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(23), 6215-6229 (2020-10-02)
Statins are cholesterol-depleting drugs used to treat patients with hypercholesterolemia. Preclinically, statins disrupt trafficking of receptors present at the cell membrane. Membrane receptors, defined as tumor biomarkers and therapeutic targets, are often internalized by an endocytic pathway. Indeed, receptor endocytosis
Bing-jiao Zhao et al.
Fundamental & clinical pharmacology, 28(5), 583-592 (2013-10-12)
Periodontal ligament stem cells (PDLSCs) are considered as potential mesenchymal stem cell sources for future clinical applications in periodontal regeneration therapy. Simvastation, widely used for lowering serum cholesterol, is known to have a bone stimulatory effect. However, it is not

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service